MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- SUN PHARMA ADV. RES.
SUN PHARMA ADV. RES. Share Price (SPARC)
Here is the latest stock price and chart of SUN PHARMA ADV. RES.. For more details, see the SUN PHARMA ADV. RES. company fact sheet and quarterly results. Since small-cap stocks interest you, here's a proven approach on investing in small-cap stocks.
WATCH NOW: Top-5 Stocks in India's $10 Trillion Rally
| Live BSE Quotes | Apr 30, 2024 (Close) | ||
|---|---|---|---|
| Price (Rs)233.10 | Open (Rs) 233.10 | High (Rs) 233.10 | Low (Rs) 233.10 |
| % Change-4.99 | Volume 32,885 | Value (Rs) 7,665,493 | 52-Week H/L 474.00 / 178.10 |
| Live NSE Quotes | Apr 30, 2024 (Close) | ||
|---|---|---|---|
| Price (Rs)232.30 | Open (Rs) 232.30 | High (Rs) 232.30 | Low (Rs) 232.30 |
| % Change-4.99 | Volume 410,800 | Value (Rs) 95,428,840 | 52-Week H/L 472.80 / 178.80 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -4.99% | 1 Month -38.33% | 3 Months -37.37% | 1 Year 19.35% | 5 Years (CAGR)* 6.70% | 10 Years (CAGR)* 3.24% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* -11.20 | P/E Ratio (x) NM | Market Cap (Rs m) 75,645.98 | P/BV (x) 34.31 | Dividend Yield (%) 0.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
SUN PHARMA ADV. RES. Share Price Today:
SUN PHARMA ADV. RES. last traded price was down 5.0% to Rs 233.1 on the BSE. On the NSE, SUN PHARMA ADV. RES. last traded price was down 5.0% to Rs 232.3. The total volume of shares traded was 0.4 m.
Overall, the benchmark S&P BSE SENSEX was at 74,482.8 (down 0.3%).
Over the last 30 days, the SUN PHARMA ADV. RES. share price is down 38.3%. And over the last one year, SUN PHARMA ADV. RES. share price is up 19.4%.
The current market capitalisation of SUN PHARMA ADV. RES. stands at Rs 75,645.98 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2024, promoter pledging in SUN PHARMA ADV. RES. stands at 2.78%. To know more, check out the latest shareholding pattern of SUN PHARMA ADV. RES..
FAQs on SUN PHARMA ADV. RES.
What is the SUN PHARMA ADV. RES. share price today?
The last traded price of SUN PHARMA ADV. RES. was Rs 233.1 on the BSE, down 5.0% over the previous close. On the NSE, SUN PHARMA ADV. RES. last traded price was down 5.0% at Rs 232.3.
What is the market cap of SUN PHARMA ADV. RES.?
The current market capitalisation of SUN PHARMA ADV. RES. stands at Rs 75,646 m.
What is the Earnings per share (EPS) of SUN PHARMA ADV. RES.?
SUN PHARMA ADV. RES. had an EPS of Rs -11.2 in the latest financial year.
Today's Market
![Sensex Today Ends 189 Points Lower | IT Stocks Drag | REC Rallies 10%, Hitachi Energy 9%]()
Sensex Today Ends 189 Points Lower | IT Stocks Drag | REC Rallies 10%, Hitachi Energy 9%(Closing)
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.